SRR25617868
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- HYPOXIA+0.190
- GLYCOLYSIS+0.140
- OXIDATIVE_PHOSPHORYLATION+0.120
- UV_RESPONSE_DN+0.120
- ADIPOGENESIS+0.090
- ESTROGEN_RESPONSE_EARLY+0.090
- MYC_TARGETS_V2+0.060
- UNFOLDED_PROTEIN_RESPONSE+0.050
- DNA_REPAIR+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.450
- IL6_JAK_STAT3_SIGNALING-0.440
- COMPLEMENT-0.380
- E2F_TARGETS-0.380
- G2M_CHECKPOINT-0.380
- INFLAMMATORY_RESPONSE-0.370
- KRAS_SIGNALING_UP-0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0063_T1_RNA | — | C | 0.830 |
| 2 | SRR25617895 | — | B | 0.805 |
| 3 | TCGA-UF-A7JK-01A-11R-A34R-07 | — | — | 0.800 |
| 4 | TCGA-B6-A0RN-01A-12R-A084-07 | — | B | 0.800 |
| 5 | SRR8613793 | — | B | 0.787 |
| 6 | MBCProject_3896_T4_RNA | — | C | 0.785 |
| 7 | SAMN03290937 | — | — | 0.777 |
| 8 | TCGA-A8-A08T-01A-21R-A00Z-07 | — | B | 0.771 |
| 9 | MBCProject_0343_T1_RNA | — | B | 0.769 |
| 10 | SRR35579848 | — | B | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.120 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |